Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autodesk Inc (ADSK) vs Quest Diagnostics Inc (DGX) Price & Performance

Autodesk IncTrade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Autodesk Inc vs Quest Diagnostics Inc — how do they compare? Autodesk Inc trades at $251.75 (market cap $53.12B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.21B). The key difference: Autodesk Inc is far larger — about 2× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Autodesk Inc pays none. Which is the better fit depends on your goals.

ADSKDGX
Market Cap
$53.12B$26.21B
Sector
TechnologyHealth
52-Week High
$326.79$238.50
52-Week Low
$187.72$173.49
Enterprise Value
$52.92B$31.97B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autodesk Inc

Autodesk (ADSK) trades at $247.39, down 3.39% in the latest session, but maintains strong fundamentals with consistent earnings beats and robust revenue growth. The stock shows a bullish technical trend with moving averages supporting upside momentum, while RSI levels indicate potential overbought conditions. Recent financial performance demonstrates expanding profit margins and healthy cash flow generation, supported by the company's dominant position in design software markets.

The outlook remains positive with analyst consensus favoring continued growth, though elevated valuation multiples and competitive pressures present risks. Upside potential exists toward the $302.23 consensus price target, supported by strong institutional backing and strategic AI investments. Key risks include market volatility and execution challenges in maintaining premium valuation levels.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.

The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.

Returns comparison

Trailing returns across standard periods

About Autodesk Inc

Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.

Read more on ADSK

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX